Skip to main content

Table 1 Genotype, tumour characteristics and endocrine therapy of the total study population (n = 226), including both oestrogen receptor (ER)-positive and ER-negative patients

From: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Characteristic Genotype [n (%)]
  CYP2D6*1/*1 CYP2D6*1/*4 CYP2D6*4/*4 SULT1A1*1/*1 SULT1A1*1/*2 SULT1A1*2/*2
Nodal involvementa, tumour size
   Node-, >30 mm 19 (76.0) 5 (20.0) 1 (4.0) 6 (24.0) 11 (44.0) 8 (32.0)
   Node+, ≤ 20 mm 66 (74.2) 18 (20.2) 5 (5.6) 30 (33.7) 49 (55.1) 10 (11.2)
   Node+, >20 mm 77 (68.8) 32 (28.6) 3 (2.7) 43 (38.4) 59 (52.7) 10 (8.9)
Receptor statusb
   ER-negative 50 (74.6) 12 (17.9) 5 (7.5) 23 (34.3) 35 (52.2) 9 (13.4)
   ER-positive 109 (69.9) 43 (27.6) 4 (2.6) 56 (35.9) 82 (52.6) 18 (11.5)
Endocrine therapy
   Tamoxifen 77 (68.8) 28 (25.0) 7 (6.3) 37 (33.0) 60 (53.6) 15 (13.4)
   No tamoxifen 85 (74.6) 27 (23.7) 2 (1.8) 42 (36.8) 59 (51.8) 13 (11.4)
  1. aNodal involvement: node+, node-positive; node-, node-negative.
  2. bER data from three patients were missing.